Detalles de la búsqueda
1.
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Oncologist
; 28(12): e1248-e1258, 2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37260332
2.
Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials.
Clin Gastroenterol Hepatol
; 18(5): 1121-1132.e2, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31442599
3.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2367-2377, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30360969
4.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Lancet
; 389(10066): 266-275, 2017 01 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27988142
5.
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Br J Clin Pharmacol
; 84(12): 2779-2789, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30088677
6.
A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.
Invest New Drugs
; 34(2): 184-92, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26792581
7.
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects.
Br J Clin Pharmacol
; 82(1): 139-48, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26852904
8.
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
Ann Rheum Dis
; 72(5): 741-4, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23161899
9.
CXCR4 as a novel target in immunology: moving away from typical antagonists.
Future Drug Discov
; 4(2): FDD77, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35875591
10.
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
Rheumatol Ther
; 7(1): 173-190, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912462
11.
Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.
J Virol
; 82(1): 435-50, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17942551
12.
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Arthritis Res Ther
; 20(1): 57, 2018 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29566740
13.
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Arthritis Rheumatol
; 69(10): 1949-1959, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28622463
14.
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Drug Metab Lett
; 10(1): 38-48, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26693854
15.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Clin Pharmacokinet
; 54(8): 859-74, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681059
16.
Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls.
J Neuroimmunol
; 137(1-2): 164-76, 2003 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-12667661
Resultados
1 -
16
de 16
1
Próxima >
>>